跳转到主要内容
搜索

Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software